Rock Springs Capital Management
Latest statistics and disclosures from Rock Springs Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, LLY, MDGL, MIRM, ARGX, and represent 26.22% of Rock Springs Capital Management's stock portfolio.
- Added to shares of these 10 stocks: MDGL (+$16M), Minimed Group (+$16M), BSX (+$7.3M), HTFL (+$7.2M), PTCT (+$6.8M), INDV (+$6.1M), SYK, MIRM, NVO, UNH.
- Started 11 new stock positions in VKTX, INDV, NVO, ORKA, DNTH, SYK, BCRX, IPSC, CVS, AGL. Minimed Group.
- Reduced shares in these 10 stocks: , CDTX (-$45M), FOLD (-$28M), XBI (-$25M), TVTX (-$22M), RVMD (-$12M), COGT (-$8.7M), RAPT (-$7.2M), Gossamer Bio (-$6.6M), LLY (-$6.2M).
- Sold out of its positions in Agilon Health, CDTX, EXACT Sciences Corporation, Gossamer Bio, MRSN, NUVB.WS, RAPT, Indivior, TBPH.
- Rock Springs Capital Management was a net seller of stock by $-161M.
- Rock Springs Capital Management has $1.7B in assets under management (AUM), dropping by -13.00%.
- Central Index Key (CIK): 0001595725
Tip: Access up to 7 years of quarterly data
Positions held by Rock Springs Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rock Springs Capital Management
Rock Springs Capital Management holds 100 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 6.9 | $118M | -9% | 1.2M | 97.25 |
|
| Eli Lilly & Co. (LLY) | 5.4 | $91M | -6% | 99k | 919.77 |
|
| Madrigal Pharmaceuticals (MDGL) | 5.3 | $90M | +22% | 171k | 523.47 |
|
| Mirum Pharmaceuticals (MIRM) | 4.4 | $75M | +6% | 811k | 92.38 |
|
| Argenx Se Sponsored Adr (ARGX) | 4.2 | $72M | -4% | 99k | 730.25 |
|
| Rhythm Pharmaceuticals (RYTM) | 3.5 | $60M | 690k | 86.97 |
|
|
| Insmed Com Par $.01 (INSM) | 3.0 | $51M | 314k | 163.52 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 2.6 | $44M | -4% | 194k | 228.73 |
|
| Xenon Pharmaceuticals (XENE) | 2.6 | $44M | -3% | 763k | 58.15 |
|
| Travere Therapeutics (TVTX) | 2.6 | $44M | -33% | 1.5M | 29.71 |
|
| Kymera Therapeutics (KYMR) | 2.4 | $41M | 497k | 83.29 |
|
|
| Penumbra (PEN) | 2.3 | $40M | 121k | 328.37 |
|
|
| Intuitive Surgical Com New (ISRG) | 2.2 | $38M | 82k | 460.99 |
|
|
| Scholar Rock Hldg Corp (SRRK) | 2.1 | $36M | 740k | 49.16 |
|
|
| Enliven Therapeutics (ELVN) | 1.9 | $32M | +3% | 827k | 39.20 |
|
| Boston Scientific Corporation (BSX) | 1.9 | $32M | +29% | 515k | 62.75 |
|
| Irhythm Technologies (IRTC) | 1.8 | $31M | +11% | 262k | 118.02 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.8 | $31M | -14% | 640k | 48.20 |
|
| Agios Pharmaceuticals (AGIO) | 1.6 | $27M | 799k | 33.83 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 1.5 | $26M | -3% | 1.2M | 20.95 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.4 | $25M | +3% | 74k | 330.87 |
|
| Cogent Biosciences (COGT) | 1.4 | $24M | -26% | 624k | 38.49 |
|
| Tenet Healthcare Corp Com New (THC) | 1.4 | $24M | 125k | 188.71 |
|
|
| Dex (DXCM) | 1.3 | $22M | +2% | 356k | 62.80 |
|
| Celldex Therapeutics Com New (CLDX) | 1.2 | $21M | -6% | 650k | 31.72 |
|
| Vera Therapeutics Cl A (VERA) | 1.2 | $20M | -11% | 504k | 40.23 |
|
| Neurocrine Biosciences (NBIX) | 1.2 | $20M | +19% | 151k | 131.74 |
|
| Arcellx Common Stock (ACLX) | 1.1 | $20M | 170k | 114.82 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.1 | $19M | 589k | 32.01 |
|
|
| Pharvaris N V (PHVS) | 1.1 | $18M | +3% | 646k | 28.25 |
|
| Erasca (ERAS) | 1.1 | $18M | +15% | 1.1M | 16.18 |
|
| Dyne Therapeutics (DYN) | 1.0 | $18M | +6% | 972k | 18.13 |
|
| Compass Therapeutics (CMPX) | 1.0 | $18M | -15% | 3.3M | 5.29 |
|
| Aclaris Therapeutics (ACRS) | 1.0 | $17M | 4.5M | 3.75 |
|
|
| Tarsus Pharmaceuticals (TARS) | 0.9 | $16M | -13% | 225k | 70.15 |
|
| Minimed Group | 0.9 | $16M | NEW | 1.1M | 14.92 |
|
| Zai Lab Adr (ZLAB) | 0.9 | $15M | 815k | 18.81 |
|
|
| UnitedHealth (UNH) | 0.8 | $14M | +29% | 53k | 270.59 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.8 | $14M | +8% | 352k | 39.72 |
|
| Heartflow Inc/Sh (HTFL) | 0.8 | $14M | +106% | 573k | 24.33 |
|
| Ardelyx (ARDX) | 0.8 | $14M | 2.3M | 5.99 |
|
|
| Summit Therapeutics (SMMT) | 0.8 | $14M | 710k | 18.96 |
|
|
| Brooks Automation (AZTA) | 0.7 | $12M | 569k | 21.13 |
|
|
| Mineralys Therapeutics (MLYS) | 0.7 | $12M | +2% | 440k | 27.09 |
|
| Danaher Corporation (DHR) | 0.7 | $12M | 62k | 189.60 |
|
|
| Ptc Therapeutics I (PTCT) | 0.6 | $11M | +161% | 162k | 68.13 |
|
| Caris Life Sciences (CAI) | 0.6 | $10M | -18% | 563k | 17.88 |
|
| Zenas Biopharma (ZBIO) | 0.6 | $9.8M | 502k | 19.55 |
|
|
| Bicara Therapeutics (BCAX) | 0.6 | $9.7M | +13% | 489k | 19.89 |
|
| Bridgebio Pharma (BBIO) | 0.6 | $9.5M | +23% | 128k | 74.26 |
|
| Soleno Therapeutics (SLNO) | 0.5 | $8.6M | +4% | 257k | 33.48 |
|
| Mbx Biosciences (MBX) | 0.5 | $8.6M | 288k | 29.85 |
|
|
| Tango Therapeutics (TNGX) | 0.5 | $8.1M | 387k | 20.92 |
|
|
| Regeneron Pharmaceuticals (REGN) | 0.5 | $7.8M | 10k | 772.64 |
|
|
| Immunome (IMNM) | 0.4 | $7.6M | 348k | 21.87 |
|
|
| Amylyx Pharmaceuticals (AMLX) | 0.4 | $6.9M | 500k | 13.90 |
|
|
| Omada Health (OMDA) | 0.4 | $6.8M | -26% | 541k | 12.57 |
|
| Inspire Med Sys (INSP) | 0.4 | $6.8M | 132k | 51.58 |
|
|
| Apellis Pharmaceuticals (APLS) | 0.4 | $6.5M | +8% | 163k | 40.23 |
|
| Alkermes SHS (ALKS) | 0.4 | $6.5M | +32% | 184k | 35.36 |
|
| Evolent Health Cl A (EVH) | 0.4 | $6.1M | 2.7M | 2.28 |
|
|
| Indivior Pharmaceuticals (INDV) | 0.4 | $6.1M | NEW | 200k | 30.48 |
|
| Terns Pharmaceuticals (TERN) | 0.4 | $6.0M | +4% | 114k | 52.72 |
|
| Edap Tms S A Sponsored Adr (EDAP) | 0.3 | $5.1M | +7% | 1.4M | 3.72 |
|
| Janux Therapeutics (JANX) | 0.3 | $5.1M | +2% | 367k | 13.90 |
|
| Phreesia (PHR) | 0.3 | $5.0M | -31% | 600k | 8.38 |
|
| Thermo Fisher Scientific (TMO) | 0.3 | $4.9M | 10k | 491.53 |
|
|
| Stryker Corporation (SYK) | 0.3 | $4.9M | NEW | 15k | 328.59 |
|
| Sionna Therapeutics (SION) | 0.2 | $4.0M | 99k | 40.09 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 0.2 | $3.9M | 180k | 21.60 |
|
|
| Spdr Series Trust State Street Spd (XBI) | 0.2 | $3.8M | -86% | 30k | 127.73 |
|
| Alphatec Hldgs Com New (ATEC) | 0.2 | $3.8M | +15% | 350k | 10.88 |
|
| Vaxcyte (PCVX) | 0.2 | $3.5M | +28% | 60k | 58.11 |
|
| Eyepoint Com New (EYPT) | 0.2 | $3.3M | 259k | 12.89 |
|
|
| Novo-nordisk A S Adr (NVO) | 0.2 | $3.3M | NEW | 90k | 36.75 |
|
| Ocular Therapeutix (OCUL) | 0.2 | $3.3M | +10% | 384k | 8.47 |
|
| Viking Therapeutics (VKTX) | 0.2 | $3.1M | NEW | 96k | 32.54 |
|
| Cytokinetics Com New (CYTK) | 0.2 | $3.0M | +26% | 45k | 65.91 |
|
| Century Therapeutics (IPSC) | 0.2 | $2.9M | NEW | 1.3M | 2.26 |
|
| CVS Caremark Corporation (CVS) | 0.2 | $2.9M | NEW | 40k | 71.82 |
|
| Roivant Sciences SHS (ROIV) | 0.2 | $2.7M | +9% | 97k | 27.70 |
|
| Talphera Com New (TLPH) | 0.2 | $2.7M | 3.6M | 0.75 |
|
|
| Olema Pharmaceuticals (OLMA) | 0.1 | $2.5M | +73% | 170k | 14.91 |
|
| Surgery Partners (SGRY) | 0.1 | $2.5M | -32% | 208k | 11.92 |
|
| Lenz Therapeutics (LENZ) | 0.1 | $2.4M | 258k | 9.15 |
|
|
| Edwards Lifesciences (EW) | 0.1 | $2.3M | -64% | 29k | 80.08 |
|
| Dianthus Therapeutics (DNTH) | 0.1 | $2.2M | NEW | 27k | 83.92 |
|
| Neurogene (NGNE) | 0.1 | $2.1M | 104k | 20.16 |
|
|
| Agilon Health Com New (AGL) | 0.1 | $2.1M | NEW | 260k | 7.91 |
|
| Corcept Therapeutics Incorporated (CORT) | 0.1 | $2.0M | 50k | 40.31 |
|
|
| Acadia Healthcare (ACHC) | 0.1 | $1.8M | -37% | 76k | 23.39 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 0.1 | $1.4M | 46k | 30.12 |
|
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.1 | $1.2M | 62k | 18.64 |
|
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 0.1 | $1.1M | +228% | 5.8k | 189.05 |
|
| Jasper Therapeutics Com New (JSPR) | 0.1 | $965k | 1.1M | 0.88 |
|
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.0 | $733k | +19% | 41k | 18.09 |
|
| Gossamer Bio (GOSS) | 0.0 | $529k | -50% | 1.6M | 0.33 |
|
| Amicus Therapeutics (FOLD) | 0.0 | $305k | -98% | 21k | 14.46 |
|
| Oruka Therapeutics (ORKA) | 0.0 | $202k | NEW | 4.1k | 49.05 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.0 | $120k | NEW | 13k | 9.52 |
|
Past Filings by Rock Springs Capital Management
SEC 13F filings are viewable for Rock Springs Capital Management going back to 2013
- Rock Springs Capital Management 2026 Q1 filed May 15, 2026
- Rock Springs Capital Management 2025 Q4 filed Feb. 17, 2026
- Rock Springs Capital Management 2025 Q3 filed Nov. 14, 2025
- Rock Springs Capital Management 2025 Q2 filed Aug. 14, 2025
- Rock Springs Capital Management 2025 Q1 filed May 15, 2025
- Rock Springs Capital Management 2024 Q4 filed Feb. 14, 2025
- Rock Springs Capital Management 2024 Q3 filed Nov. 14, 2024
- Rock Springs Capital Management 2024 Q2 filed Aug. 14, 2024
- Rock Springs Capital Management 2024 Q1 filed May 15, 2024
- Rock Springs Capital Management 2023 Q3 filed Nov. 14, 2023
- Rock Springs Capital Management 2023 Q2 filed Aug. 14, 2023
- Rock Springs Capital Management 2023 Q1 filed May 15, 2023
- Rock Springs Capital Management 2022 Q4 filed Feb. 14, 2023
- Rock Springs Capital Management 2022 Q3 filed Nov. 14, 2022
- Rock Springs Capital Management 2022 Q2 filed Aug. 15, 2022
- Rock Springs Capital Management 2022 Q1 filed May 16, 2022